Table 1.
Descriptive table of demographics overall and differentiated into < 20 kg and ≥ 20 kg groups expressed as number (%). Details are included to describe median total fluid administered, incidence of adverse events, median day 7 eGFR, and median length of stay
| Characteristic | < 20 kg group N = 28 |
≥ 20 kg group N = 74 |
Overall N = 102 |
|
|---|---|---|---|---|
|
Age at transplant, years Median (IQR) |
4 (2) | 14 (4) | 12.5 ( 9) | |
|
Weight, kg Median (IQR) |
14.5 (4.5) | 45.4 (23) | 39.8 (30.9) | |
|
Gender N (%) |
Male | 17 (60.7) | 43 (58.1) | 60 (58.8) |
| Female | 11 (39.3) | 31 (41.9) | 42 (41.1) | |
|
Ethnicity N (%) |
White/White British/other White | 19 (67.8) | 39 (52.7) | 58 (56.9) |
| Black/Black African/Black Caribbean/other Black | 3 (10.7) | 6 (8.1) | 9 (8.8) | |
| Mixed ethnicity | 0 | 5 (6.7) | 5 (4.9) | |
| Asian Pakistani/Indian/Bangladeshi | 3 (10.7) | 18 (24.3) | 21 (20.6) | |
| Other | 1 (3.5) | 6 (8.1) | 7 (6.9) | |
| Unknown | 2 (7.1) | 0 | 2 (2) | |
|
Type of transplant N (%) |
Living donation | 20 (71.4) | 36 (48.7) | 56 (54.9) |
| Deceased donation | 8 (28.6) | 38 (51.3) | 46 (45.1) | |
|
Underlying diagnosis N (%) |
CAKUT | 13 (46.4) | 27 (36) | 40 (39.2) |
| ARPKD | 2 (7.1) | 2 (2.7) | 4 (3.8) | |
| Denys–Drash syndrome | 0 | 1 (1.4) | 1 (1) | |
| Vasculitides | 1 (3.5) | 1 (1.4) | 2 (1.9) | |
| Congenital nephrotic syndrome | 3 (10.7) | 1 (1.4) | 4 (3.8) | |
| Alport syndrome | 0 | 1 (1.4) | 1 (1) | |
| Manz syndrome | 0 | 1 (1.4) | 1 (1) | |
| Unknown | 2 (7.1) | 8 (10.8) | 10 (9.5) | |
| Cystinosis | 0 | 1 (1.4) | 1 (1) | |
| Cortical necrosis as a neonate | 0 | 1 (1.4) | 1 (1) | |
| HBNF1B | 1 (3.5) | 1 (1.4) | 2 (1.9) | |
| PUV | 1 (3.5) | 14 (18.9) | 15 (14.3) | |
| Nephrotic syndrome | 1 (3.5) | 4 (5.4) | 5 (4.8) | |
| HUS/TMA | 0 | 2 (2.7) | 2 (1.9) | |
| Nephronophthisis | 0 | 6 (8.1) | 6 (5.7) | |
| Alagille syndrome | 1 (3.5) | 0 | 1 (1) | |
| Joubert syndrome | 0 | 2 (2.7) | 2 (1.9) | |
| Wilms tumour | 2 | 0 | 2 (1.9) | |
| Stromme syndrome | 1 (3.5) | 0 | 1 (1) | |
| Primary sclerosing glomerulonephritis | 0 | 1 (1.4) | 1 (1) | |
|
Total fluid administered ml/kg Median (IQR) |
507 (225.5) | 356 (139) | 374.5 (148) | |
|
Occurrence of adverse events N (%) |
Pulmonary oedema | 3 (10.7) | 11 (14.8) | 14 (13.7) |
| Hypertension | 13 (4.6) | 40 (54) | 53 (52) | |
| Oxygen requirement | 6 (21.4) | 25 (33.7) | 31 (30.4) | |
| Unplanned PICU admission | 3 (10.7) | 6 (8.1) | 9 (8.8) | |
| Delayed graft function | 1 (3.5) | 2 (2.7) | 3 (2.9) | |
|
Day 7 eGFR, ml/min/1.73 m2 Median (IQR) |
135 (60.3) | 69.9 (42.7) | 84.1 (57.6) | |
|
Length of stay Median (IQR) |
10 (4) | 10 (6) | 10 (5) |